The NK cell checkpoint NKG2A maintains expansion capacity of human
4.7 (506) · € 16.99 · Auf Lager
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer, Stem Cell Research & Therapy
HLA-E and NKG2A as a novel immune checkpoint axis to improve treatment for non-muscle invasive bladder cancer
Harnessing NK Cell Memory for Cancer Immunotherapy.
Cancers, Free Full-Text
JCI - Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
ExCellerate™ Human NK Cell Expansion Media, Xeno-Free CCM032: R&D Systems
Human leukocyte antigens: the unique expression in trophoblasts and their crosstalk with local immune cells
Harnessing the Power of Natural Killer Cells for Cancer Immunotherapy
PDF) The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
PDF) The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
NK cell-based tumor immunotherapy - ScienceDirect
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy
Bispecific Antibody Designed for Targeted NK Cell Activation and Functional Assessment for Biomedical Applications
Senescent T cells: a potential biomarker and target for cancer therapy - eBioMedicine
